v2021a Search Results


incucyte software  (Sartorius AG)
99
Sartorius AG incucyte software
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Incucyte Software, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/incucyte software/product/Sartorius AG
Average 99 stars, based on 1 article reviews
incucyte software - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
c4d / complement 4d antibody  (NSJ Bioreagents)
92
NSJ Bioreagents c4d / complement 4d antibody
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
C4d / Complement 4d Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c4d / complement 4d antibody/product/NSJ Bioreagents
Average 92 stars, based on 1 article reviews
c4d / complement 4d antibody - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
track manager v2021.03.1  (QUALISYS LIMITED)
90
QUALISYS LIMITED track manager v2021.03.1
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Track Manager V2021.03.1, supplied by QUALISYS LIMITED, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/track manager v2021.03.1/product/QUALISYS LIMITED
Average 90 stars, based on 1 article reviews
track manager v2021.03.1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
originpro v2021b software  (OriginLab corp)
90
OriginLab corp originpro v2021b software
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Originpro V2021b Software, supplied by OriginLab corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/originpro v2021b software/product/OriginLab corp
Average 90 stars, based on 1 article reviews
originpro v2021b software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cavalieri estimator  (MBF Bioscience)
90
MBF Bioscience cavalieri estimator
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Cavalieri Estimator, supplied by MBF Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cavalieri estimator/product/MBF Bioscience
Average 90 stars, based on 1 article reviews
cavalieri estimator - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
xlstat software  (Addinsoft inc)
90
Addinsoft inc xlstat software
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Xlstat Software, supplied by Addinsoft inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xlstat software/product/Addinsoft inc
Average 90 stars, based on 1 article reviews
xlstat software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
two-way, repeated measures anova  (ncss llc)
90
ncss llc two-way, repeated measures anova
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Two Way, Repeated Measures Anova, supplied by ncss llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/two-way, repeated measures anova/product/ncss llc
Average 90 stars, based on 1 article reviews
two-way, repeated measures anova - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
rstudio v2021.09.0–351  (RStudio)
90
RStudio rstudio v2021.09.0–351
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Rstudio V2021.09.0–351, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rstudio v2021.09.0–351/product/RStudio
Average 90 stars, based on 1 article reviews
rstudio v2021.09.0–351 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
scils lab v2024a pro  (Bruker Corporation)
97
Bruker Corporation scils lab v2024a pro
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Scils Lab V2024a Pro, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/scils lab v2024a pro/product/Bruker Corporation
Average 97 stars, based on 1 article reviews
scils lab v2024a pro - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
machine learning toolbox in matlab  (MathWorks Inc)
96
MathWorks Inc machine learning toolbox in matlab
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Machine Learning Toolbox In Matlab, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/machine learning toolbox in matlab/product/MathWorks Inc
Average 96 stars, based on 1 article reviews
machine learning toolbox in matlab - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
origin software v2021  (OriginLab corp)
90
OriginLab corp origin software v2021
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Origin Software V2021, supplied by OriginLab corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/origin software v2021/product/OriginLab corp
Average 90 stars, based on 1 article reviews
origin software v2021 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
vivado design suite user guide—getting started; ug910 (v2021.2)  (Xilinx Inc)
90
Xilinx Inc vivado design suite user guide—getting started; ug910 (v2021.2)
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Vivado Design Suite User Guide—Getting Started; Ug910 (V2021.2), supplied by Xilinx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vivado design suite user guide—getting started; ug910 (v2021.2)/product/Xilinx Inc
Average 90 stars, based on 1 article reviews
vivado design suite user guide—getting started; ug910 (v2021.2) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) IncuCyte killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.

Journal: Journal for Immunotherapy of Cancer

Article Title: EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

doi: 10.1136/jitc-2024-009486

Figure Lengend Snippet: EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) IncuCyte killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.

Article Snippet: Results were analyzed using IncuCyte software (Sartorius, V.2021A).

Techniques: Functional Assay, Construct, Flow Cytometry, Expressing, Co-Culture Assay, Positive Control, Transduction, Plasmid Preparation, Cell Culture